Structured population data were available for 3 of 3 supporting studies. 1 study described participants with type 2 diabetes. 3 studies described adult participants.

1 supporting study does not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: placebo, usual_care.

2 of 3 studies with duration data have follow-up of 12 weeks or less.

Available source content was suppressed because validation identified a conflict.

Standard care for diabetes management

Core clinician-reference fields are available or not applicable.

Participants receiving oral semaglutide for primary prevention of cardiovascular events.

Oral Semaglutide Group

ASCEND PLUS is a randomised controlled trial assessing the effects of oral semaglutide on the primary prevention of cardiovascular events in around 20,000 individuals with type 2 diabetes in the UK.

Participants receiving standard care for diabetes management.

The trial includes a comparator group receiving standard care for diabetes management.

Authoritative quality diagnostic: invalid or missing timepoint.

Authoritative quality diagnostic: invalid or missing unit.

Authoritative quality diagnostic: invalid or missing value.

Oral semaglutide may improve cardiovascular event prevention in type 2 diabetes.

Placebo

Patients with type 2 diabetes and high-risk chronic kidney disease receiving semaglutide.

Semaglutide

1767 were randomized to semaglutide, and 1766 were randomized to placebo.

Patients with type 2 diabetes and high-risk chronic kidney disease receiving placebo.

Semaglutide improves cardiovascular outcomes in high-risk patients

Participants received weekly injectable semaglutide 2.4 mg.

Semaglutide 2.4 mg

In SELECT, people with overweight or obesity and atherosclerotic cardiovascular disease without diabetes were randomized to weekly semaglutide 2.4 mg or placebo.

Semaglutide may reduce cardiovascular events in non-diabetic patients.

Structured population data were available for 7 of 7 supporting studies. 6 studies described participants with type 2 diabetes. 7 studies described adult participants.

4 supporting studies do not have a displayable topic-matched quantitative effect.

3 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

1 study contains conflicting p-value and significance fields; those significance claims are suppressed.

Structured population data were available for 4 of 4 supporting studies. 3 studies described participants with type 2 diabetes. 4 studies described adult participants.

Upstream consistency scoring indicates mixed findings across the evidence.

2 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Structured population data were available for 6 of 6 supporting studies. 4 studies described participants with type 2 diabetes. 6 studies described adult participants.

1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.

Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 3 studies described adult participants.

Semaglutide × Cardiovascular events

Available supporting studies

Oral semaglutide may improve cardiovascular event prevention in type 2 diabetes.

Semaglutide improves cardiovascular outcomes in high-risk patients

Semaglutide may reduce cardiovascular events in non-diabetic patients.